<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934166</url>
  </required_header>
  <id_info>
    <org_study_id>15084A</org_study_id>
    <secondary_id>2012-005711-53</secondary_id>
    <nct_id>NCT01934166</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects</brief_title>
  <official_title>An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to infinity (AUC0-inf)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to time t (t being the time for last quantifiable concentration) (AUC0-t)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: maximum observed concentration (Cmax)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: nominal time corresponding to the occurrence of Cmax (tmax)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: apparent elimination half life in plasma (t½)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene and the metabolite nalmefene 3-O-glucuronide: renal Clearance (CLR)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene: oral clearance for nalmefene defined as dose/AUC0-inf (CL/F)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For nalmefene: apparent volume of distribution for nalmefene (Vz /F)</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For the metabolite nalmefene 3-O-glucuronide: metabolic ratio (MR) defined as AUC0-inf,metabolite/AUC0-inf,parent</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 10 days</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Nalmefene 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene 18 mg</intervention_name>
    <description>One single oral dose of 18 mg</description>
    <arm_group_label>Nalmefene 18 mg</arm_group_label>
    <other_name>Selincro®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy young subjects and subjects with renal impairment with a Glomerular Filtration
             Rate (GFR) of 50-80 ml/min/1.73m2, 30-&lt;50 ml/min/1.73m2, &lt;30 ml/min/1.73m2 will be
             included in the study.

          -  The subjects must have a BMI between 19 and 32 kg/m2.

        Exclusion Criteria:

          -  The subject has a history of renal transplant or is undergoing dialyse treatment.

          -  The subject is, in the opinion of the investigator, unlikely to comply with the
             protocol or is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DE801</name>
      <address>
        <city>Munich</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

